In arthritis patients, however, findings are controversial regarding the association of FCGR3A polymorphisms with clinical response to TNF-α inhibitors (infliximab, adalimumab, etanercept): although one study describes a better clinical response in FCGR3A-F/F158 patients (68); another, larger study with a more homogenous patient cohort found no association (69). Here, FCGR3A is linked to arthritic joint disease.